- Conditions
- HIV Infections
- Interventions
- Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 8,651
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Interventions
- Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
- Conditions
- Post Herpetic Neuralgia
- Interventions
- NXN-462, Placebo
- Drug
- Lead sponsor
- NeurAxon Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Migraine, Without Aura
- Interventions
- sumatriptan succinate / naproxen sodium, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 70
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
- Conditions
- Asthma
- Interventions
- Ginger Extract, Placebo
- Drug
- Lead sponsor
- Emily DiMango, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin 9, 39, Placebo
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Lubiprostone, Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more
- Conditions
- Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases, Diabetes, Cardiovascular Disease, Glucose Metabolism Disorders, Hypertension
- Interventions
- Omega-3, Placebo
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Covid19
- Interventions
- Placebo, Fisetin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Dysautonomia, Familial, Baroreflex Failure Syndrome
- Interventions
- Carbidopa Low-Dose, Placebo, Carbidopa High-Dose
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Amyloidosis; Systemic
- Interventions
- AT-02, AT-02 (Placebo)
- Drug · Other
- Lead sponsor
- Attralus, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Overland Park, Kansas • Baltimore, Maryland • Kansas City, Missouri + 3 more
- Conditions
- Asthma
- Interventions
- Fluticasone Furoate, Fluticasone Propionate, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more
- Conditions
- Pain, Cannabis, Opioid Use, Unspecified
- Interventions
- Within-subject test of blinded study medications
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- DYT-1, Dystonia
- Interventions
- Ampicillin, Sugar pill
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 7 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Schizophrenia
- Interventions
- Iclepertin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Anaheim, California • Culver City, California • Los Angeles, California + 19 more
- Conditions
- Healthy Subjects
- Interventions
- CDX-0159, Normal saline
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Diabetic Gastroparesis, Idiopathic Gastroparesis
- Interventions
- TAK-906 Maleate, Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 67
- States / cities
- Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
- Conditions
- Hypertriglyceridemia, Cardiovascular Diseases
- Interventions
- ISIS 678354, Placebo
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 24
- States / cities
- Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
- Conditions
- Acute Depressive Episode
- Interventions
- Ramelteon SL, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 141
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 137 more
- Conditions
- Autoimmune Epilepsy
- Interventions
- Intravenous Immunoglobulin, Placebos, Normal Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Smoking, Smoking Cessation
- Interventions
- Oxytocin, Mindfulness, Saline Solution, Sham mindfulness
- Drug · Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sjögrens Disease
- Interventions
- Abiprubart, Placebo
- Drug
- Lead sponsor
- Kiniksa Pharmaceuticals International, plc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Menifee, California • Poway, California • Whittier, California + 13 more